AMENDMENT OF SOLICITATION
Solicitation Number: HHS-NIH-NIAID-BAA2017-1
Amendment Number: 1

AMENDMENT ONE (1)

Issued by:
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Acquisitions
5601 Fishers Lane, 3rd Floor
Bethesda, MD  20892

Solicitation Number:
HHS-NIH-NIAID-BAA2017-1

Date of Solicitation Issuance: Date of Amendment No.1 Issuance:
03/03/2017 03/17/2017

Number of Pages: Attachments:
2 Pages HHS-NIH-NIAID-BAA2017-1 – Amendment 1

Primary Point of Contact:
George Kennedy, Contracting Officer
Email: kennedyg@mail.nih.gov
Phone: 240-669-5170

Offerors MUST acknowledge receipt of the amendment by Amendment number(s) and date of the amendment.

FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.

Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.
Purpose of Amendment 1: Revision of Proposal Receipt Date and Time

This purpose of this amendment is twofold:

1) **Research Area 001 DAIT, “Adjuvant Development Program”:** The date for receipt of proposals is revised from 05/30/2017 to 06/13/2017;


Accordingly, subparagraph A. “Receipt Date”, is revised as follows:

**A. Receipt Date**

This BAA includes five distinct Research Areas, each with a specified closing date and time, identified below. An Offeror must submit a separate and distinct proposal for each Research Area to which it wishes to propose:

<table>
<thead>
<tr>
<th>RESEARCH AREA</th>
<th>NIAID DIVISION</th>
<th>TITLE</th>
<th>RECEIPT DATE AND TIME:</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>DAIT</td>
<td>Adjuvant Development Program</td>
<td>3:00 PM, Eastern Time, 06/13/2017</td>
</tr>
<tr>
<td>002</td>
<td>DAIT</td>
<td>Development of Radiation/Nuclear Medical Countermeasures</td>
<td>3:00 PM, Eastern Time, 05/30/2017</td>
</tr>
<tr>
<td>003</td>
<td>DAIT</td>
<td>Development of Radiation/Nuclear Predictive Biomarkers and Biodosimetric Devices</td>
<td>3:00 PM, Eastern Time, 05/30/2017</td>
</tr>
<tr>
<td>004</td>
<td>DMID</td>
<td>Development of Broad Spectrum Therapeutic Products for Biodefense, Anti-Microbial Resistant Infections and Emerging Infectious Diseases</td>
<td>3:00 PM, Eastern Time, 07/03/2017</td>
</tr>
<tr>
<td>005</td>
<td>DMID</td>
<td>Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases</td>
<td>3:00 PM, Eastern Time, 07/03/2017</td>
</tr>
</tbody>
</table>

The revised solicitation: “HHS-NIH-NIAID-BAA2017-1 – Amendment One”, is attached hereto, incorporating the revision identified above.

End of Amendment 1